Elizabeth Parrish, CEO

Elizabeth Parrish CEO is a humanitarian, entrepreneur and innovator, is a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of regenerative medicine modalities, she serves as a motivational speaker to the public at large for the life sciences. She is actively involved in international educational media outreach and sits on the board of the International Longevity Alliance (ILA). READ MORE

Jason Williams, CMO

Dr. Williams is a radiologist with a passion for gene and cellular therapies that can be administered under image guidance. He also has an interest in image guided cancer therapies. He did research for several years with adenoviral vector technology for the treatment of cancer. He has spent the last five years involved in research using AAV technology. READ MORE

Avi Roy, CTO

Dr. Roy - is a Regenerative Medicine specialist, and a top level scientific advisor to politicians, and industrialist from around the world. Avi did his research on biomarkers of aging at the University of Oxford, and at the University of Buckinghamn. Avi is an Oxford based biomedical scienntist, and has co-founded several non-profit institutions for the public dessemination of science. READ MORE

Stefania Schino

Stefania Schino is a project manager and public funding expert.
After she received her bachelor's degree in Accounting and Finance from Bari University of Economy she worked for many years as a consultant to help companies improve investments and strategic planning. Her expertise is in European public funding, under the Horizon 2020 program, as well as national and regional grants. READ MORE

David Kekich

David A. Kekich is a recognized authority on longevity science. In 1999, he founded "Maximum Life Foundation", a 501(c)(3) not-for-profit corporation dedicated to reversing human aging and aging related diseases. Since then, the Foundation, in concert with many of the world’s leading researchers, has developed a scientific road map to transform the elderly to biological youth. READ MORE

Anca Selariu, CSO

Dr.
Anca Selariu has twelve years of biomedical research in herpesviruses and transmissible spongiform encephalopathies, and three years in cGMP project management and business development. She earned her PhD at Rutgers NJ, where she developed an alternative vaccine for chickenpox and shingles. Her education includes a Bachelor’s degree in Biochemistry and another in Philology, as well as courses in astrobiology, psychology, criminology,and nutrition.
READ MORE

Please Join Us!

We are gene therapy innovation leaders. We develop platforms to treat severe genetic disorders and cellular aging. We are working on several patents and are seeking strategic partnerships to help us make a positive step forward in our efforts to bring cures to aging populations and those who suffer monogenic disease. At the heart of Bioviva's product creation efforts is its broadly applicable gene therapy platform for the development of novel one time treatments for diseases with either ineffective or no clinical options.